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Purpose: To investigate the role of serum inflammatory cytokines and vascular endothelial growth factor (VEGF) in
diabetic retinopathy (DR) and evaluate their relationship with macular thickness measurements obtained with optical
coherence tomography (OCT).
Methods: The study enrolled 28 healthy subjects (Group 1), 31 patients without DR (Group 2), 49 patients with
nonproliferative DR (Group 3), and 46 patients with proliferative DR (Group 4). Macular profile was assessed with Stratus
OCT-3 and the serum concentrations of VEGF and interleukin-1α (IL-1α), interleukin-6 (IL-6), interleukin-8 (IL-8),
interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte chemoattractant protein (MCP-1), and
epidermal growth factor (EGF) were measured using multiplex bead immunoassay.
Results: The median value of the visual acuity was 20/20 (Groups 1 and 2), and 20/100 (Group 3), and 20/125 (Group
4). The median value of central subfield macular thickness was estimated as 165.50 μm in Group 1, 202.5 μm in Group
2, 318 μm in Group 3, and 310 μm in Group 4. The median serum VEGF level, which was 98.20 pg/ml in Group 1,
demonstrated a progressive rise to 125.37 pg/ml in Group 2, to 153.07 pg/ml in Group 3, and to 149.12 pg/ml in Group
4. Statistical significance was found between all groups (p<0.05) except between Groups 3 and 4 (p=0.87). The median
levels of IL-1α and IL-6 were zero in all groups. The median serum levels of IL-8, IL-10, MIP-1α, and EGF revealed a
wide range within each group but no statistical significance between the groups (p>0.05). The median serum levels of
IL-8, IL-10, MIP-1α, and EGF revealed a wide range within each group, however, no statistically significant relationship
was found between the groups (p>0.05). The median values of the serum MCP-1 concentrations presented a statistically
significant rise with the progression of DR (p=0.02). No correlation was found between macular thickness and serum
cytokine and VEGF levels (p>0.05).
Conclusions: Increased serum levels of VEGF and MCP-1 may act as a key regulator of DR and provide a potential tool
for risk assessment in diabetic patients. Further studies that evaluate both vitreous and serum levels in various stages of
DR are needed to provide a better understanding of the interaction between systemic and local inflammatory and
angiogenic factors.
Diabetic retinopathy (DR) is one of the most debilitating
complications  of  diabetes  mellitus  (DM).  Although
proliferative  retinopathy  may  lead  to  loss  of  vision  and
blindness, diabetic macular edema (DME) is the main cause
of central vision loss. The Wisconsin Epidemiological Study
for Diabetic Retinopathy found DME in 3%–29% out of 1121
patients who are 30 years or older at the time of diagnosis
[1] and DME is demonstrated to be responsible for blindness
in 72% out of 64 blind patients due to DR [2].
DME is a multifactorial burden of DM including risk
factors  like  duration  of  diabetes,  insulin  dependence,
glycosylated  hemoglobin,  proteinuria,  hypertension  in
addition to panretinal laser photocoagulation, and traction of
the posterior hyaloid [3-5]. It is mainly caused by leakage of
intravascular fluid from microaneurysms and abnormal retinal
capillaries into the intraretinal and subretinal space due to
hyperpermeability  related  to  general  blood-retina  barrier
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(BRB) breakdown. This hyperpermeability is the ultimate
result of a cascade of biochemical and cellular changes [6].
In recent years mounting evidence has emerged about the
role of cytokines, inflammatory cells, growth factors, and
angiogenic factors in the pathogenesis of diabetic retinopathy.
These studies support the hypothesis that DR is a low grade,
subclinical inflammatory disease; however the majority of
them included patients with advanced DR who underwent
vitrectomy and therefore lack comparison of findings with
patients without DR or early DR. In these studies the levels of
cytokines  were  determined  with  ELISA  [7-10].  Luminex
multiplex  bead  immunoassay,  is  a  new  technology  which
employs  uniquely  labeled  fluorescent  microspheres
conjugated  to  anti-cytokine  capture  antibodies  and  allows
analysis  of  all  molecules  from  one  sample  [11].  The
technology  effectively  allows  multiple  cytokines  to  be
analyzed simultaneously from small volume samples (25–
100  μl/test),  reducing  time,  cost,  and  effort,  making  this
technology  a  valid  alternative  method  to  ELISA.  The
measurements with Luminex technology also show excellent
correlations with ELISA [12,13].
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1906Our study aimed to elucidate serum levels of the most
debated cytokines and chemokines including interleukin-1α
(IL-1α),  interleukin-6  (IL-6),  interleukin-8  (IL-8),
interleukin-10  (IL-10),  macrophage  inflammatory  protein
(MIP-1α),  monocyte  chemoattractant  protein  (MCP-1),
epidermal  growth  factor  (EGF),  and  vascular  endothelial
growth factor (VEGF) in subjects with DM and the healthy
subjects by using the multiplex bead immunoassay. We also
evaluated the relationship between serum cytokine levels and
macular  thickness  measurements  obtained  with  optical
coherence tomography (OCT).
METHODS
In this prospective study, we enrolled 154 participants: 126
patients with type 2 DM and 28 age-matched healthy control
participants.  Informed  consent  was  obtained  from  all
participants, in accordance with the tenets of the Declaration
of Helsinki, and the study was approved by the Ethics Review
Board of the Selcuk University. The diabetic patients were
recruited  from  the  Retina  Service,  Department  of
Ophthalmology,  Selcuk  University  Hospitals.  Control
participants were nondiabetic individuals who had visited the
Ophthalmology Department at Selcuk University for routine
examination or prescription of eyeglasses. Ocular exclusion
criteria  were  intraocular  surgery,  intravitreal  therapy,
photocoagulation, trauma, vitreous hemorrhage, and retinal
detachment in the preceeding six months and history of any
ocular inflammatory disease like uveitis. Also excluded were
DR patients who presented with DME related to posterior
hyaloid  traction.  Systemic  exclusion  criteria  included
ischemic cerebrovascular disorders, ischemic cardiovascular
disorder, hyperlipidemia, renal dysfunction (serum creatinine
concentration >1.5 mg/dl), hepatic dysfunction (serum ALT
>32 IU/l, serum AST>40 IU/I), hematological disease, any
systemic inflammatory disease and history of malignancy. All
participants  underwent  comprehensive  ophthalmologic
examination  that  included  best  corrected  visual  acuity,
applanation  tonometry,  slit-lamp  examination,  and  dilated
fundus  examination.  Based  on  international  clinical  DR
disease severity scale [14], participants were divided into four
groups: 28 control participants (Group 1), 31 patients without
DR (Group 2), 49 nonproliferative DR patients (Group 3), and
46 proliferative DR patients (Group 4). DM patients were
classified based on the. The mean age of the control group was
64.2±8.22  years  and  that  of  the  diabetic  patients  were
62.5±7.87 years.
The  eye  with  the  lower  Snellen  visual  acuity  of  all
participants was selected for the study. The macular profile
was assessed with the fast macular scan protocol of the OCT-3
(Carl Zeiss Meditec, Inc., San Leandro, CA) through dilated
pupil  and  by  the  same  physician  (B.T.O).  This  protocol
consisted of six line scans that were 6 mm long, centered on
fixation,  and  spaced  30  degrees  apart  around  the
circumference of a circle. The mean central subfield macular
thickness of each eye was recorded for the analysis. For the
correlation analysis we preferred the central subfield macular
thickness instead of foveolar thickness which is a mean value,
generated by the Stratus OCT software from the central A-
scan thickness values of the six radial lines comprising the fast
macular  thickness  map.  In  contrast  the  central  subfield
macular thickness is computed from 21 points from each of
the  six  radial  lines  and  was  reported  to  provide  a  better
representation  for  the  central  retina  because  of  its  higher
reproducibility and correlation with other measurements of
the central macula [15].
Blood samples were obtained from all participants by
venous puncture and sent to the laboratory. The glycosylated
hemoglobin  (HbA1c)  level  was  assessed.  The  remaning
sample is centrifugated at 1000 g for 10 min after which the
harvested serum was stored at −80 °C until assayed.
Cytokine assay: IL-1α, IL-6, IL-8, IL-10, EGF, MCP-1,
MIP-1α, and VEGF were measured in serum samples using
Luminex  multiplex  bead  immunoassay  (Human  Cytokine
LINCOplex  kit;  LINCO  Research,  St.  Charles,  MO).
Multiplex bead kits were purchased from Linco Research, Inc.
(catalog number HCYTO-60K). The assay was performed
according to the manufacturer’s instructions with Luminex
laser  based  fluorescent  analytical  test  instrumentation.
Standard curves for each cytokine were generated by using
the  reference  cytokine  concentrations  supplied  by  the
manufacturer.  The  value  “zero”  represented  undetectable
levels of the cytokine.
Statistical  analysis:  Data  were  analyzed  using  the
statistical package for the social sciences (SPSS version 15.0)
for  Windows.  Group  differences  between  diabetics  and
controls  were  analyzed  using  one-way  ANOVA  or
nonparametric Kruskal–Wallis tests, depending on normality
assumptions and homogeneity of variances. The parameters
showing statistically significant difference among all groups
were further analyzed using Mann–Whitney-U test or Student
t-test.  The  correlations  between  study  parameters  were
analyzed  by  Spearman’s  correlation  test.  All  tests  were
performed at an error level of 5%.
RESULTS
With regard to age (p=0.24) and sex (p=0.61) distribution, no
significant difference was observed between the study groups
as presented in Table 1. The median value of DM duration
was 10 years in Group 2, 12 years in Group 3, and 15 years in
Group 4 (p<0.001; Table 1).
The  HbA1c  values  between  4.27%–6.07%  were
considered as normal in our laboratory. The mean HbA1c
level in control group was 5.69±0.53%. The mean HbA1c
level was 7.95±2.06% in Group 2, 8.10±1.61% in Group 3,
and 8.53±2.11% in Group 4 (Table 2). This increase of HbA1c
levels with progression of DR was found to be statistically
significant (p=0.02). The median value of the visual acuity
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20/100 in Group 3 and 20/125 in Group 4. This decrease was
also  found  to  be  statistically  significant  (p<0.001).  The
median  value  of  central  subfield  macular  thickness  was
estimated as 165.50 μm in Group 1, 202.5 μm in Group 2,
318 μm in Group 3, and 310 μm in Group 4. Statistical analysis
showed significant differences between the groups (p<0.001)
and also correlation with visual acuity (r=-0.6, p<0.001; Table
2).
There  was  significant  variation  between  the  cytokine
concentrations. These values showed a remarkable overlap
among the study groups. The median serum level of vascular
endothelial growth factor (VEGF) was 98.20 pg/ml in the
control  group,  125.37  pg/ml  in  DM  patients  without  DR
(Group  2),  153.07  pg/ml  in  nonproliferative  DR  patients
(Group 3), and 149.12 pg/ml in the proliferative DR patients
(Group 4; Table 3). These higher serum VEGF levels in the
DR groups as demonstrated in Figure 1 were found to be
statistically  significant  (p=0.04).  The  statistical  analysis
revealed  a  significant  difference  in  serum  VEGF  levels
between Group 1 and Group 3 (p=0.01) and between Group
1  and  Group  4  (p=0.02),  but  there  were  no  statistically
significant  differences  between  Group  3  and  Group  4
(p=0.87).
The median levels of serum IL-1α and IL-6 were zero in
all subgroups. Serum IL-1 could not be detected in 23 subjects
in Group 1, 27 subjects in Group 2, 45 subjects in Group 3 and
36  subjects  in  Group  4.  Twelve  subjects  in  Group  1,  20
subjects in Group 2, 29 subjects in Group 3 and 26 subjects in
Group 4 demonstrated undetected levels of IL-6.
The  serum  levels  of  IL-8,  IL-10,  MIP-1α,  and  EGF
revealed  a  wide  range  within  each  group,  however  no
statistically  significant  relationship  was  found  among  the
subgroups. Serum IL-10 could not be detected in 11 members
of group 1; the median value was 3.34 pg/ml. However, 22
subjects in group 2, 31 subjects in group 3 and 31 subjects in
group 4 demonstrated a level of zero, so the median value in
these groups was calculated as zero.
The median values of the serum MCP-1 concentrations
presented a statistically significant rise with the progression
of DR (p=0.03; Figure 2; Table 3). There was no statistically
significant difference between Group 1 and Group 2 (p=0.31),
but  the  difference  between  Group  3  and  Group  4  was
significant (p=0.02).
Serum  cytokines  and  VEGF  levels  did  not  show  a
correlation  with  age  and  gender  (Table  4).  However  the
duration of DM was found to correlate with serum VEGF
(r=0.19, p=0.02), IL-8 (r=0.27, p=0.001), MCP-1 (r=0.30,
p=0.00), and EGF levels (r=0.18, p=0.03).
Serum HbA1c levels revealed a significant correlation
with IL-10 and MCP-1 levels (r=-0.25 p=0.005 and r=0.18
p=0.05 respectively), however there was no correlation with
TABLE 1. DISTRIBUTION OF AGE, SEX, AND DIABETES DURATION BETWEEN GROUPS.
  Group 1
(Control)
(n=28)
Group 2 
(No retinopathy)
(n=31)
Group 3 
(Nonproliferative retinopathy)
                    (n=49)
Group 4 
(Proliferative retinopathy)
               (n=46)
p value*
Age 64.2±8.22 63.9±9.50 63.2±8.08 60.9±6.14 0.24
Sex Female 16 (57.14%) 17 (54.84%) 32 (65.31%) 24 (52.17%)              0.61
Male 12 (42.86%) 14 (45.16%) 17 (34.69%) 22 (47.82%)
Duration of diabetes
mellitus (years)
Median value (range)
[Mean±standard deviation]
0 10.0 (1-20)
[9.84±7.13]                           [12.54±6.16]                    [15.89±6.99]
           12.0 (1-30)                                  15.0 (1-30)                              <0.001
The comparison of groups enrolled in the present study revealed no statistically significant difference for age and sex. The
duration  of diabetes mellitus (DM) increased in the DR groups (Group3 and 4) and statistical analysis demonstrated a significant
difference. The asterisk indicates the data of one-way ANOVA test.
TABLE 2. COMPARISON OF HBA1C LEVELS, VISUAL ACUITY, AND CENTRAL SUBFIELD MACULAR THICKNESS VALUES BETWEEN GROUPS.
 
 Group 1                                    Group 2
(Control)                           (No retinopathy)
 (n=28)                                (n=31)
Group 3 
(Nonproliferative retinopathy)
                       (n=49)
Group 4 
(Proliferative retinopathy)
                   (n=46)
p
value*
HbA1c (%) 5.69±0.53 7.95±2.06 8.10±1.61 8.53±2.11 0.02
Visual acuity
Medianvalues (range)
20/20 (20/32–20/20) 20/20 (20/40- 20/20) 20/100 (<20/400–20/20) 20/125 (<20/400–20/25) <0.001
Macular thickness (μm)
Median values (range)
165.5 (159–194) 202.5 (125–277) 318 (185–670) 310 (153–573) <0.001
With regard to HbA1c levels, visual acuity and central subfield macular thickness values, there was a statistically significant
difference  between study groups. The asterisk indicates the data of one-way ANOVA test. Abbreviations: DR represents diabetic
retinopathy.
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1908serum VEGF levels (r=0.04 p=0.63). The serum VEGF levels
were estimated to be correlated with IL-6, IL-8, MIP-1α,
MCP-1 and EGF levels (p<0.05 for all) and MCP-1 levels
were  found  to  be  correlated  with  HbA1c  and  VEGF  as
mentioned above and with IL-8, MIP and EGF levels (p<0.001
for all). A correlation between the amount of macular edema
quantified  with  the  measurement  of  the  central  subfield
macular  thickness  and  the  serum  levels  of  the  studied
cytokines and VEGF was lacking according to the correlation
analysis (p>0.05; Table 4).
DISCUSSION
Despite advances in ophthalmological care, DR remains a
major cause of preventable blindness [16]. Current therapeutic
strategies  indicate  that  a  better  understanding  of  the
pathogenesis is crucial for an improved management of DR.
It has been recognized that the metabolic control, reflected by
the blood glucose level and glycosylated hemoglobin value,
is an important factor for the onset and progression of DR.
Nevertheless  the  precise  pathogenic  mechanism  of  DR  is
unclear already [17].
DME, the primary clinical feature associated with visual
impairment, is known to occur from the leakage of plasma into
the central retina. This results in stretching and distortion of
neurons and leads to reversible reduction in visual acuity.
Over time, the perturbed neurons die, resulting in permanent
visual loss [18]. The leakage may be focal or diffuse. Focal
leakage might occur due to leakage from microaneurysms.
These microaneurysms resulted from the retinal vessel wall
weakening and impairment of the BRB due to hyperglycemia
induced pericyte death. In contrast diffuse leakage is related
to the microscopic damage of retinal vessels described as BRB
breakdown and increased permeability factors like IL-6 and
VEGF [5].
TABLE 3. SERUM CONCENTRATIONS OF VEGF AND CYTOKINES IN THE STUDY GROUPS
    Group 1 
                   (Control)
(n=28)
        Group 2 
(No retinopathy)
(n=31)
Group 3
(Nonproliferative retinopathy)
 (n=49)
Group 4 
(Proliferative retinopathy)
                  (n=46) p value*
VEGF 
(pg/ml)
M±SD 100.47±49.66 137.29±84.45 177.07±119.51 169.88±109.12 0.04
Mdn 98.20 125.37 153.07 149.12
Range (32.46–186.93) (24.30–445.76) (30.03–547.74) (31.56–487.02)
IL-1α 
(pg/ml)
M±SD 13.15±32.40 5.31±19.07 3.40±12.76 99.78±484.66 0.24
Mdn 0 0 0 0
Range           (0–136.17) (0–98.6) (0–64.15) (0–3255.24)
IL-6                      M±SD 4.06±5.29 4.01±9.13 7.98±19.03 23.78±91.55 0.74
Mdn 0 0 0 0
Range                       (0–16.99) (0–43.64) (0–101.18) (0–564.62)
IL-8                    M±SD 36.10±37.92 104.76±182.93 88.40±115.45 110.99±157.96 0.29
Mdn                            18.83 11.96 44.19 37.64
Range                   (6.72–142.62) (0–697.97) (0–552.88) (0–775.42)
IL-10 
(pg/ml)
M±SD 17.57±42.93 8.13±24.17 18.43±42.54 42.15±202.57 0.31
Mdn                             3.34 0 0 0
Range                      (0–208.27)                             (0–128.61) (0–220.19) (0–1362.73)
MIP-1α 
(pg/ml)
M±SD 10.68±14.92 9.63±13.46 13.08±21.97 169.51±1061.659.15 0.4
Mdn                             4.69 0 6.91 (0–7212.84)
Range                       (0–64.65) (0–41.94) (0–120.24)
MCP-1 
(pg/ml)
M±SD 154.42±58.29 193.26±103.75 192.37±78.54 311.61±488.61 0.03
Mdn                             159.0 167.95 195.56 226.59
Range                    (44.29–243.0) (46.42–434.28) (0–377.19) (96.80–3475.76)
EGF                   M±SD 146.60±86.80 180.29±129.16 169.56±106.92 189.18±93.82 0.41
Mdn                            147.67 152.22 150.21 172.39
Range                    (7.94–321.46) (13.07–551.87) (8.34–484.07) (39.28–421.02)
Serum  levels  of  inflammatory  cytokines  including  interleukin-1α  (IL-1α), interleukin-6  (IL-6),  interleukin-8  (IL-8),
interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte chemoattractant protein (MCP-1), epidermal
growth factor (EGF), showed a statistically significant difference between groups only for MCP-1. The serum levels of vascular
endothelial growth factor (VEGF) increase in the diabetic retinopathy (DR) groups which were found to be statistically
significant as well. The asterisk indicates data of the Kruskal–Wallis variance analysis. Abbreviations: M±SD represents mean
± standard deviation, Mdn represents median.
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(pg/ml)
(pg/ml)DR displays all microscopic signs of inflammation such
as vasodilatation, altered flow, fluid exudation and leukocyte
migration. Therefore chronic low grade inflammation seems
to be an inciting and final common pathway leading to DR.
(8).  Alterations  in  serum  or  vitreous  levels  of  many
inflammatory cytokines like IL-6, IL-8, IL-10, and VEGF also
supports the role of inflammation in DR [10,19-21].
VEGF is the most attractive candidate for stimulating
new vessel formation and vascular hyperpermeability in DR.
It is a mitogen for endothelial cells, and its expression both in
vivo and in vitro can be induced by hypoxia [22,23]. Retinal
hypoxia-induced inflammation and increased expression of
VEGF has been implicated in the pathogenesis of DME [24].
The pivotal role of VEGF in DME is further supported with
the  studies  that  showed  regression  of  DME  after  the
intravitreal injection of anti-VEGF drugs [25].
In the literature, the association of serum VEGF levels
with DR are conflicting. Most of the studies evaluating both
vitreous and serum VEGF levels have found increased VEGF
levels in diabetics compared to controls [26-28]. In our study,
serum  VEGF  levels  were  also  significantly  higher  in  the
diabetic group compared to controls, with the highest values
observed in DR group. However, there was no significant
difference between the nonproliferative DR group (Group 3)
and the proliferative DR group (Group 4; p=0.87), which may
be an explanation for the lack of correlation with HbA1c levels
(Table  3).  Meleth  et  al.  [26]  found  also  no  significant
difference  in  serum  VEGF,  IL-6,  and  IL-8  levels  among
subjects  with  less  severe  and  severe  DR.  In  contrast
Cavusoglu et al. [26] detected progressively increasing serum
levels  of  VEGF  in  DR  and  correlation  with  the  stage  of
retinopathy and HbA1c levels. The high levels of VEGF in
the serum of patients with DR both in our study and that of
Cavusoglu may support its role in development of retinopathy.
IL-6 is a multifunctional cytokine that indirectly causes
an increase in vascular permeability and neovascularization
by inducing the expression of VEGF [29]. It can also directly
increase endothelial cell permeability in vitro by rearranging
actin filaments and by changing the shape of endothelial cells
[30]. Serum levels of IL-6 and TNF- α are proposed to be
predictor of proliferative retinopathy development [31]. IL-8
has been recognized as a potent chemoattractant activator of
neutrophils and T lymphocytes but not monocytes [32]. In the
study of Murugeswari et al. [33], the vitreous levels of IL-6,
IL-8,  MCP-1  and  VEGFs  were  significantly  higher  in
proliferative DR and serum levels of IL-8, VEGF and MCP-1
were  below  the  vitreous  levels,  which  elucidate  a  local
inflammatory process in DR. In the study Hernandez et al.
[10], vitreous levels of IL-8 and MCP-1 were found to be
increased in proliferative DR. Meleth et al. [28] could not find
any difference in serum IL-6 and IL-8 levels between less
severe and severe DR and the percentage of subjects with
undetectable serum levels of IL-8 and IL-6 .was over 80%. In
the study of Doganay et al. [20], the levels of serum IL-6 were
below the detection limits of the assay in all patients with DM
and controls and IL-8 levels were found to be highest in
Figure 1. Distribution of serum VEGF
concentrations  within  the  groups.
Boxplot  analysis  showing  increased
serum  levels  of  vascular  endothelial
growth factor (VEGF) in patients with
diabetes  mellitus  (DM)  compared  to
control  subjects.  The  median  serum
VEGF  levels  were  higher  in  diabetic
subjects  with  retinopathy  than  those
without.  Abbreviations:  DR(-)
represents  patients  without  diabetic
retinopathy.
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1910proliferative DR group. In our study, serum IL-6 could not be
detected in 58% of DR group and 43% of control subjects.
Both serum IL-6 and IL-8 did not different among the study
groups.
IL-1α is a proinflammatory cytokine that has pleiotrophic
and  overlapping  functions  and  is  neuroprotective  in  CNS
[34]. In this study, serum IL-1α levels did not differ between
healthy subjects and diabetic patients, which might be due to
the undetectable serum levels of IL-1α in the majority of
subjects. In the study of Doganay et al. [20], the levels of
IL-1β were below the detection levels in all DR patients and
healthy controls.
Another cytokine evaluated in our study was IL-10, an
anti-inflammatory cytokine produced primarily by monocytes
and macrophages [35]. Lee et al. [31] found that higher serum
IL-10 levels are related to lower risk of DR in DM patients.
Supporting this finding, our study noted higher serum IL-10
levels in control participants compared to diabetic patients.
However,  a  statistically  proven  relationship  was  lacking
(p=0.31).
Figure 2. Distribution of serum MCP-1
levels  within  the  groups.  Boxplot
analysis  of  serum  monocyte
chemoattractant protein (MCP-1) levels
in  diabetic  patients  demonstrated  an
increase  with  progression  of  diabetic
retinopathy (DR). Abbreviations: DR(-)
represents  patients  without  diabetic
retinopathy.
TABLE 4. CORRELATION ANALYSIS OF AGE, GENDER, DURATION OF DIABETES MELLITUS, HBA1C LEVELS AND MACULAR THICKNESS.
  Age                              Gender                      Duration of DM
                              Coefficient p                   Coefficient p                    Coefficient p
     HbA1c
Coefficient p
Macular thickness
     Coefficient p
VEGF −0.01 0.89 −0.06 0.44 0.19 0.03 0.04 0.63 0.06 0.5
IL-1α             0.03 0.73 0 0.95 −0.05 0.51 −0.08 0.36 0.06 0.49
IL-6 −0.05 0.55 −0.11 0.16 0.03 0.7 −0.03 0.7 0 1
IL-8 0.1 0.22 −0.02 0.81 0.27 0 −0.03 0.77 0.13 0.16
IL-10 0.14 0.08 0 0.98 −0.04 0.63 −0.25 0 0.11 0.21
MIP-1α            0.1 0.23 −0.06 0.44 0.13 0.11 −0.08 0.37 0.14 0.13
MCP-1 −0.06 0.46 0.02 0.82 0.3 0 0.18 0.05 0.15 0.12
EGF −0.03 0.67 0.07 0.39 0.18 0.03 −0.05 0.59 −0.01 0.91
The Spearman’s correlation analysis of the inflammatory cytokines including interleukin-1α (IL-1α), interleukin-6 (IL-6),
interleukin-8 (IL-8), interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte chemoattractant protein
(MCP-1), epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF), with age, gender and macular
thickness showed no correlation. Duration of diabetes mellitus (DM) correlated with serum VEGF, IL-8, MCP-1, and EGF
levels and HbA1c levels correlated with IL-10 and MCP-1 levels. The coefficients were calculated from the Spearman’s
correlation test p<0.05.
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1911Chemokines are small molecular weight proteins that
guide the migration of responsive cells. Cells attracted by
chemokines shows chemoattraction in addition to leukocyte
activation. They are categorized into four subgroups: CXC,
CC, C, and CX3X. MIP-1α and MCP-1 are members of the
CC chemokines [36].
MCP-1 is a chemokine that recruits immune cells such as
monocytes and lymphocytes [37]. It is produced by retinal
endothelial cells and has been implicated in leukostasis of the
hypoxic retina [28,38]. Hyperglycemia has also been shown
to increase the expression of MCP-1 by vascular endothelial
cells [39]. A positive regulatory feedback loop between VEGF
and MCP-1 expression by vascular endothelial cells has been
also suggested [9]. Previous data proposed that MCP-1 is a
potential angiogenic factor in the proliferative phase of DR
[10,21,40]. Mitamura et al. [40] and Hernández et al. [10]
found a significant association between MCP-1 levels in the
vitreous and the degree of proliferation in DR. Maier et al.
[21]  showed  a  positive  correlation  of  HbA1c  levels  with
vitreous  MCP-1  levels,  but  could  not  find  a  correlation
between MCP-1 levels and stage of DR. Our data demonstrate
correlation of MCP-1 with the progression of DR and also
with HbA1c levels, VEGF, IL-8, and MIP-1α.
MIP-1α  is  produced  by  macrophages  and  activates
human  granulocytes  such  as  neutrophils,  eosinophils,
basophils, and monocytes. MIP-1α also induces the release of
proinflammatory interleukins such as IL-1 or IL-6 [41]. In the
mouse model, MIP-1α has been identified as a potent inducer
of retinal neovascularization [42]. Hanifi-Moghaddam et al.
[43] observed an upregulation in serum levels of MIP-1α in
patients with type 1 DM. In contrast,in the study of Capeans
et al. [44] MIP-1α levels have been noted to be below the
detection levels in both diabetics and controls. Our study
showed  an  upregulation  of  MIP-1α  in  the  diabetic  group
compared  to  controls.  This  finding  was  not  considered
significant  statistically.  However,  we  found  a  significant
correlation with IL-6, IL-8, IL-10, and VEGF supporting its
role in retinal neovascularization.
Several  growth  factors  have  been  implicated  in  the
development  of  preretinal  fibrovascular  membranes  in
proliferative DR [45,46]. One of these factors is EGF, which
is known to be a potent migrator as well as a cell migration
and differentiation modulator. It is still a matter of debate as
to whether EGF is of systemic origin or is derived locally from
retina [47]. The insignificant difference of serum EGF levels
between control subjects and diabetic patients with different
stages of DR found in our study is in accordance with the study
of Patel et al. [47] and infers local production of EGF in DR.
To the best of our knowledge, our study is the first that
evaluated the correlation of serum cytokines and VEGF levels
with macular thickness of diabetic patients with DME and
found no correlation (Table 4). Similar to our study, Petrovic
et al. [27] found no differences in serum VEGF levels between
DM patients with and without macular edema and with and
without  active  neovascularization.  But  the  presence  of
macular edema was based only on clinical examination in their
study. Patel et al. [8] evaluated the vitreous and aqueous levels
of VEGF and detected the highest vitreous levels in the NPDR
group  followed  by  the  proliferative  DR  group.  They
additionally  divided  subjects  with  DME  into  two  groups
according  to  the  macular  profile:  Group  1  with  posterior
hyaloid traction and Group 2 with diffuse low elevation of
macula. The vitreous and aqueous VEGF levels in Group 2
were  higher  compared  to  Group  1,  which  supports  the
hyperpermeability hypothesis in this group of DME. Funatsu
et al. [48] also demonstrated a correlation between vitreous
VEGF, ICAM, IL-6, MCP-1, and PEDF levels with DME
severity. Regarding these findings, the lack of correlation
between macular thickness and serum VEGF levels in our
study  might  indicate  the  importance  of  local  VEGF
production in DME [8,48]. However we could not compare
the serum levels of the abovementioned cytokines and VEGF
with vitreous levels, since none of the subjects consented an
invasive procedure like vitreous tap.
Another reason for the lack of correlation between serum
cytokine levels and VEGF with DME might be the effect of
other microvascular diabetic complications on serum levels.
Increasing  evidence  highlights  the  importance  of
inflammatory  mechanisms  in  the  development  and
progression  of  other  microvascular  diabetic  complications
such as neuropathy and nephropathy [49,50]. Therefore we
excluded  diabetic  subjects  with  nephropathy  to  evaluate
directly the relationship between serum cytokines and DME.
However, it did not completely eliminate the effect of other
organs on serum levels of cytokines and VEGF, since it is
recognized that features of inflammation are displayed years
before the onset of complications.
In conclusion, we suggest that increased serum levels of
VEGF and MCP-1 may act as a key regulator of DR and
provide a potential tool for risk assessment of DR. Further
studies comparing both vitreous and serum levels in various
stages of DR are needed to provide a better understanding of
the interaction between systemic and ocular inflammatory and
angiogenic factors
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